2016-02-15T16:33:01-07:00 2015-06-30 990 2014-07-01 730580274 OKLAHOMA MEDICAL RESEARCH FOUNDATION OKLA 4052717421 825 NE 13th Street Oklahoma City OK 73104 Tim Hassen Chief Financial Officer 4052717421 2016-02-15 2014 2016-08-17 19:52:53Z Tim Hassen VP and CFO 825 NE 13th Street Oklahoma City OK 73104 67446706 0 X www.omrf.org X 1946 OK OMRF is dedicated to developing a better understanding of and more effective treatments for human disease. 74 74 543 0 0 0 55978368 51927439 5774897 6952995 3026034 2973763 4688610 4202579 69467909 66056776 0 0 0 0 33893582 35520534 0 0 1828230 37667116 36927376 71560698 72447910 -2092789 -6391134 401849018 392496683 61913600 60801464 339935418 331695219 OMRF is dedicated to developing a better understanding of and more effective treatments for human disease. 0 0 18505822 0 13570642 Arthritis & Clinical Immunology/Clinical Operations - In November, a blue-ribbon panel of independent scientific advisors from Duke, Stanford and other leading academic institutions reviewed this group of researchers who study lupus, multiple sclerosis and other diseases in which the body mistakenly turns the immune system against itself. Their verdict? "Nowhere in the world is there a better program than this one," they told OMRF's board of directors. By blending laboratory research with patient studies, program leader Dr. Judith James and her colleagues have created a model for how physicians and scientists can work together to create better outcomes for patients. This partnership between researchers and clinicians spurred the publication of 68 new research studies this past year, including dozens on the molecular mechanisms of lupus and one that showed how MS patients' bodies reacted to particular treatments. Researchers in this program also secured major grants to study a pair of debilitating but poorly understood autoimmune illnesses: sarcoidosis and Sjogren's syndrome. Ultimately, says James, "The goal is that these and related studies will help improve the lives of patients with these diseases." 5681334 0 6862953 Cardiovascular Biology Research Program - Scientists in this program focus their research on the blood-how it flows, how it clots and how blood vessels grow. This work is fundamental to understanding and treating a wide variety of diseases, and in 2015 research in this program led down many different paths. Important studies cast new light on how heart disease-causing plaques form in the arteries, tissue damage caused by conditions such as diabetes and stroke, and the ways in which behaviors can affect the genetic traits passed on to children and grandchildren. OMRF cardiovascular biologists also made significant progress toward the development of novel therapies for victims of traumatic injuries like gunshot wounds and motor vehicle accidents. Finally, they made a series of findings on how to prevent vascular growth. These insights could one day prove key to starving the blood supply to cancerous tumors, a mechanism that scientists will continue to explore in hopes of new therapies to treat various forms of cancer. 5336640 0 5297730 Immunobiology and Cancer Research Program - By understanding how the immune system functions, scientists in this program are able to find clues about the diseases that result when things go awry. Chief among these conditions is cancer, and OMRF researchers made significant progress on this front in 2015. In particular, their work focused on breast cancer, where research moved ahead on developing new therapies for some of the most difficult to treat forms of this deadly disease. Researchers in this program also showed that exposure to certain chemicals can interfere with a mother's ability to breastfeed her children and how the development of scarring in fatty tissues can lead to diabetes. Through a variety of innovative approaches, scientists in the program continue to make insights that touch on a broad spectrum of issues vital to human health. 36351817 0 9289930 Other Program Services 36351817 0 9289930 65875613 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 1 133 0 1 543 1 0 0 0 0 1 1 1 1 0 0 0 1 1 0 X 74 74 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 OK X X X Tim Hassen 4052717421 825 NE 13th Street Oklahoma City OK 73104 Allen Greg S Board Member 1 0 X 0 0 0 Anoatubby Bill Board member 1 0 X 0 0 0 Bell Sharon Board Member 1 0 X 0 0 0 Benbrook Bruce Board Member 1 0 X 0 0 0 Benham Lance Board Member 1 0 X 0 0 0 Boghetich Jil Board Member 1 0 X 0 0 0 Braught Barbara Board Member 1 0 X 0 0 0 Burgess Bill Board Member 1 0 X 0 0 0 Brown Randy Board Member 1 0 X 0 0 0 Burgess Ellen Board Member 1 0 X 0 0 0 Cameron Bill Board Member 1 0 X 0 0 0 Carolina Mike Board Member 1 0 X 0 0 0 Carroll Michael Board Member 1 0 X 0 0 0 Cason Len Board Member 1 0 X 0 0 0 Cawley Michael Board Member 1 0 X 0 0 0 Champlin Hiram Board Member 1 0 X 0 0 0 Collins Mark Board Member 1 0 X 0 0 0 Crawford Bill Board Member 1 0 X 0 0 0 Drake Ramsey Board Member 1 0 X 0 0 0 Duncan Walt Board Member 1 0 X 0 0 0 Eagan Claire Board Member 1 0 X 0 0 0 Edwards Carl Board Member 1 0 X 0 0 0 Evans Pat Board Member 1 0 X 0 0 0 Everest Christy Board Member 1 0 X 0 0 0 Felton Ann Board Member 1 0 X 0 0 0 Fergeson Ken Board Member 1 0 X 0 0 0 Ferree Larry Board Member 1 0 X 0 0 0 Fischer Malinda Board Member 1 0 X 0 0 0 Fretwell Barbara Board Member 1 0 X 0 0 0 Funke Mark Board Member 1 0 X 0 0 0 Gamble Gerald Board Member 1 0 X 0 0 0 Griffin John Board Member 1 0 X 0 0 0 Groendyke Virginia Board Member 1 0 X 0 0 0 Haglund Jacqui Board Member 1 0 X 0 0 0 Hall Brooks Board Member 1 0 X 0 0 0 Hargis Burns Board Member 1 0 X 0 0 0 Hawley Bill Board Member 1 0 X 0 0 0 Henry Kim Board Member 1 0 X 0 0 0 Henry Robert Board Member 1 0 X 0 0 0 Hogan Randy Board Member 1 0 X 0 0 0 Holmes Jerome Board Member 1 0 X 0 0 0 Hudson Cliff Board Member 1 0 X 0 0 0 Jameson Brett Board Member 1 0 X 0 0 0 Johnstone Bill Board Member 1 0 X 0 0 0 Kerr Lou Board Member 1 0 X 0 0 0 Levy Harrison Board Member 1 0 X 0 0 0 Little Dan Board Member 1 0 X 0 0 0 Loughridge Bill Board Member 1 0 X 0 0 0 McCarty Jack Board Member 1 0 X 0 0 0 McPherson Frank Board Member 1 0 X 0 0 0 Morris Jim Board Member 1 0 X 0 0 0 Mueller James Board Member 1 0 X 0 0 0 Nichols Larry Board Member 1 0 X 0 0 0 Parry Richard Board Member 1 0 X 0 0 0 Patten Rebecca Board Member 1 0 X 0 0 0 Payne Bond Board Member 1 0 X 0 0 0 Pierson Gary Board Member 1 0 X 0 0 0 Pitman Don Board Member 1 0 X 0 0 0 Rainbolt David Board Member 1 0 X 0 0 0 Replogle Dee Board Member 1 0 X 0 0 0 Rooney Pat Board Member 1 0 X 0 0 0 Ross Bob Board Member 1 0 X 0 0 0 Samis Mike Board Member 1 0 X 0 0 0 Saxon John Board Member 1 0 X 0 0 0 Schulte Paul Board Member 1 0 X 0 0 0 Stough Phyllis Board Member 1 0 X 0 0 0 Swimmer Ross Board Member 1 0 X 0 0 0 Switzer Becky Board Member 1 0 X 0 0 0 Taylor Steven Board Member 1 0 X 0 0 0 Thorpe Betsy Board Member 1 0 X 0 0 0 Walton Greg Board Member 1 0 X 0 0 0 Ward Lew Board Member 1 0 X 0 0 0 Williams Jr G Rainey Board Member 1 0 X 0 0 0 Wymer Deane Board Member 1 0 X 0 0 0 Prescott Stephen President and CEO 50 0 X 1013440 0 269683 Paul Kincade VP of Research & Member, Immunobiology and Cancer 50 X 261898 0 32136 Morgan Chip Executive VP & Chief Operating Officer 50 0 X 228238 0 28498 Cohen Adam Sr VP & General Counsel 50 0 X 227889 0 27345 Voss Penny VP of Development 50 0 X 202218 0 51888 Nair Manu VP of Technology Transfer 50 0 X 123488 0 24293 Hassen Tim VP and CFO 50 0 X 209527 0 32438 Day Lisa VP of Business and Government Affairs 50 0 X 113935 0 24109 Courtney Stevens VP of Human Resources 50 0 X 130708 0 21352 James Judith Program Chair, Arthritis and Clinical Immunology 50 0 X 368420 0 57529 McEver Rodger Program Chair, Cardiovascular Biology 50 0 X 303112 0 38572 Jones David Program Chair, Functional and Chemical Genomics 50 0 X 254292 0 38252 Pardo Gabriel Associate Member, Arthritis and Clinical Immunology 50 0 X 327943 0 47221 Gaffney Patrick Member, Arthritis and Clinical Immunology 50 0 X 249013 0 44706 Sivils Kathy Member, Arthiritis and Clinical Immunology 50 0 X 236792 0 34748 Tummala Saigiridhar Director of Comparative Medicine & Attending Vet 50 0 X 215910 0 32734 Nath Swapan Member, Arthritis and Clinical Immunology 50 0 X 206945 0 32054 Capra J Donald Former President 10 0 X 144000 0 0 4817768 0 837558 52 1 1 0 Infusion Management LLC 11233 Shadow Creek Pkwy Pearland TX 77584 Medical Billing Services 4688650 Aramark 24863 Network Pl Chicago IL 606731248 HouseKeeping Services 498872 Parker Highlander 1120 S Capital of Texas Hwy Bldg One Ste 200 Austin TX 78746 Legal 159673 4 142102 0 418148 0 34633731 16733458 674509 51927439 Clinic Revenue 621399 6952995 6952995 0 0 0 0 0 0 6952995 3512488 3512488 0 0 113389 113389 0 0 2430476 2430476 0 0 481352 0 0 0 481352 0 481352 481352 0 0 681506 56310 680615 709315 891 -653005 -652114 -652114 0 0 0 418148 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Cafe Income 722100 306101 306101 0 0 Laboratory Income 541380 984650 984650 0 0 0 0 0 0 1290751 66056776 14129337 0 0 3639385 2666994 770173 202218 23661715 21853709 870815 937191 8219434 7078797 844692 295945 140096 97132 42964 0 108230 75038 33192 0 222813 0 222813 0 1170286 1170286 0 0 556182 356631 62139 137412 775028 657106 70551 47371 3510473 2750351 760122 0 619905 558642 50887 10376 139845 129930 6630 3285 2547916 2466043 81873 0 8324226 7937048 387178 0 404164 280216 123948 0 Lab Supplies 5104691 5104691 0 0 Trainee Costs 1257831 1257831 0 0 Inhouse 1082304 1052088 21645 8571 Subcontracts 8925113 8925113 0 0 2038273 1457967 394445 185861 72447910 65875613 4744067 1828230 4300 5100 21875917 21660063 12604562 9834071 2813091 2129623 0 0 0 0 349231 215589 4785 4815 401899 444802 225422659 110543502 121264252 114879157 104370997 105455082 1737938 2170938 0 0 0 0 136422046 135697443 401849018 392496683 7006902 6580381 0 0 0 0 50933440 49883269 0 0 0 0 0 0 0 0 3973258 4337814 61913600 60801464 X 113170541 107390595 40602185 37606428 186162692 186698196 339935418 331695219 401849018 392496683 X -6391134 -1769032 0 0 0 -80033 X 0 1 X 1 1 1 X 69070646 56883620 51804565 55978368 51927440 285664639 0 0 0 0 0 0 0 0 0 0 0 0 69070646 56883620 51804565 55978368 51927440 285664639 43496316 242168323 6803393 6055949 6515711 7714644 7176342 34266039 0 0 0 0 0 0 0 0 0 0 0 0 319930678 6952995 0.75694 0.86642 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 222813 0 0 222813 0 Schedule C, Part II-B, Line 1 The Foundation's lobbying activities entail monitoring proposed legislation and educating legislators and their staffs about the Foundation, medical research and the impact of proposed legislation on medical research and the Foundation. 86302560 1057014 2745217 0 3500000 0 86604791 76260090 390308 12952162 0 3300000 0 86302560 66735078 3205030 9519982 0 3200000 0 76260090 69793689 76613 64776 0 3200000 0 66735078 58867420 237181 13989088 0 3300000 0 69793689 0.0708 0.6281 0.3011 1 0 3944520 0 3944520 180032409 0 78983179 101049230 0 0 0 0 41322000 0 31560323 9761677 123730 0 0 123730 114879157 Funds Held in Trust by Others 131653562 Wills and Bequests 2049453 Cash Surrender Value of Life Insurance 1339483 Debt Issue Costs 354167 Deposits 158988 Accrued Interest Receivable 93714 Assets Held for Sale 47970 Minerals 106 135697443 0 Split Interest Agreements & Other Liabilities 320836 Postretirement Benefits & Deferred Compensation 4016978 4337814 X 64207711 -1769032 0 0 -80033 -1849065 66056776 0 0 0 66056776 72447910 0 0 0 0 0 72447910 0 0 0 72447910 Schedule D, Part V, Line 4 The Foundation's endowment consists of individual funds established to provide the Foundation with funding in perpetuity. Schedule D, Part X, Line 2 Management has reviewed the Foundation's tax positions and concluded that there are no uncertain tax positions that require accrual in the financial statements or disclosure in the footnotes to be in compliance with authoritative literature. Generally, the Foundation is no longer subject to income tax examination by federal, state or local tax authorities for years prior to 2012. Schedule D, Part XI, Line 2d Pension related changes other than net periodic pension cost. 241 Event 588584 0 588584 0 346 0 21560 60727 87802 0 0 588584 0 588584 0 346 0 21560 60727 87802 170435 418149 X 1 1 X X X X X X 0 1 0 0 0 0 0 1 0 Prescott Stephen President and CEO 745982 0 222033 0 45425 0 256532 0 9812 0 1279784 0 0 0 Paul Kincade VP of Research & Member, Immunobiology and Cancer 232137 0 1500 0 28261 0 22282 0 9854 0 294034 0 0 0 Morgan Chip Executive VP & Chief Operating Officer 200313 0 0 0 27925 0 18636 0 9862 0 256736 0 0 0 Cohen Adam Sr VP & General Counsel 190452 0 200 0 37237 0 18759 0 8587 0 255235 0 0 0 Voss Penny VP of Development 182451 0 200 0 19567 0 36950 0 14938 0 254106 0 0 0 Nair Manu VP of Technology Transfer 122813 0 0 0 675 0 10018 0 14275 0 147781 0 0 0 Hassen Tim VP and CFO 207445 0 325 0 1757 0 17458 0 14980 0 241965 0 0 0 Day Lisa VP of Business and Government Affairs 109770 0 0 0 4166 0 9462 0 9462 0 132860 0 0 0 Courtney Stevens VP of Human Resources 129257 0 100 0 1351 0 10800 0 10552 0 152060 0 0 0 James Judith Program Chair, Arthritis and Clinical Immunology 346132 0 1650 0 20638 0 48222 0 9307 0 425949 0 0 0 McEver Rodger Program Chair, Cardiovascular Biology 273729 0 0 0 29383 0 28760 0 9812 0 341684 0 0 0 Jones David Program Chair, Functional and Chemical Genomics 243289 0 0 0 11003 0 23315 0 14938 0 292545 0 0 0 Pardo Gabriel Associate Member, Arthritis and Clinical Immunology 327074 0 0 0 869 0 32283 0 14938 0 375164 0 0 0 Gaffney Patrick Member, Arthritis and Clinical Immunology 234584 0 0 0 14429 0 29726 0 14980 0 293719 0 0 0 Sivils Kathy Member, Arthiritis and Clinical Immunology 225100 0 10000 0 1692 0 19048 0 15700 0 271540 0 0 0 Tummala Saigiridhar Director of Comparative Medicine & Attending Vet 197374 0 0 0 18536 0 17460 0 15274 0 248644 0 0 0 Nath Swapan Member, Arthritis and Clinical Immunology 200250 0 0 0 6694 0 17116 0 14938 0 238998 0 0 0 Capra J Donald Former President 144000 0 0 0 0 0 0 0 0 0 144000 0 0 0 Schedule J, Part I, Line 1a First class travel is allowed for the CEO to allow him to accomplish work related tasks while traveling. Schedule J, Part I, Line 3 Compensation for the CEO is determined by leadership of the board of directors based on comparability data from widely accepted peer benchmarking surveys that are segmented by region and size of entity. Schedule J, Part I, Line 4 The Board of the Foundation periodically uses nonqualified retirement plans as a retention tool. Schedule J, Part I, Line 7 The CEO receives an annual bonus that is determined by leadership of the board of directors based on performance. The bonus is considered as a portion of total compensation and is subject to the review process previously described. A Oklahoma Industries Authority 736194355 679103YC9 2008-08-14 42955000 Revenue Bonds (OMRF Project) Series 2008 0 0 0 B Oklahoma Industries Authority 736194355 XXNONEXXX 2010-05-26 12185000 Revenue Bonds (OMRF Project) Series 2010 0 0 0 A 6070000 0 43457720 3316750 0 0 141976 0 0 30540129 0 9431264 2011 0 0 0 1 B 0 0 12320300 1218339 0 0 138825 0 0 0 10963136 0 2011 0 1 1 1 A 0 0 0 1 1 0 0 0 1 0 1 B 0 0 0 1 1 0 0 0 1 0 1 A 0 0 0 1 0 0 0 1 1 B 1 0 0 0 0 1 A 1 B 1 Schedule K, Part IV, Line 2c-08/14/2008 42,955,000 Oklahoma Industries Authority No rebate was due according to the rebate calculated November 21, 2013 for the rebate period beginning May 26, 2010 through June 30, 2013. Accele Venture Partners Common Directors 366602 Equity investment 0 Accele Biopharm Common Directors 300000 Equity investment 0 Bank of Oklahoma Common Directors 111956 Investment and mineral asset management 0 X 24 674509 FMV 0 0 1 1 Schedule M, Part I, Line 32b A third party is used to sell gifts of stocks or bonds received from donors. Usually the donor transfers the stocks directly from their brokerage account into OMRF's third party account. Occasionally, OMRF receives stock certificates and those are sent directly to the third party to process. Form 990, Part VI, Section A, Line 1a The Foundation's Board of Directors has delegated all of its powers to the Foundation's Executive Committee, except as follows: establish the overall policies and direction of the Foundation, appoint the members of the Executive Committee, elect and remove the Chair of the Board of Directors, amend the Bylaws and the Certificate of Incorporation of the Foundation, and appoint special committees to the Board of Directors. The Board of Directors may at any time amend or revoke this delegation of powers. Form 990, Part VI, Section A, Line 2 The Foundation currently has 85 directors, many of whom are business leaders and members of prominent families in the State of Oklahoma. The Foundation believes there are multiple business relationships between and among board members and families of Board members, but the Foundation review of signed conflict of interest disclosures from all board members and of the Foundation's ledger accounts indicated there are no such relationships that would impair the fiduciary duties of any director to the Foundation Form 990, Part VI, Section B, Line 11b A summary of the Form 990 is presented for review to the Executive Committee. Subsequent to that review, the Form 990 with all supplemental schedules is made available to all members of the board of directors for review and comment prior to filing. Form 990, Part VI, Section B, Line 12c Each director, officer and key employee is annually provided with a copy of the Foundation's conflict of interest policy. Each of these individuals is annually provided with a questionnaire regarding potential conflicts and required to disclose any potential conflict that he or she might have. In addition, each of these individuals must annually sign a statement affirming that he or she has; received a copy of the conflicts of interest policy, read and understood the policy and agrees to comply with the policy. Once the Foundation has collected annual disclosure statements from all directors, officer and key employees, the Foundation's Governance Committee reviews such information to identify situations in which a potential conflict exists and is material. If a potential material conflict is identified, the committee analyzes whether the contemplated transaction may be authorized as just, fair, and reasonable to the Foundation. The Governance Committee then makes a recommendation to the Foundations' Executive Committee regarding the management of all potential conflicts it has identified. The final decision as to the approval and , where applicable, management of all such potential conflicts rests in the sole discretion of the Executive Committee, which makes such decisions based upon the welfare of the Foundation and the advancement of its purpose. The recommendations of the Governance Committee and decisions of the Executive Committee are documented in the respective minutes of these Committees' regular meetings. Form 990, Part VI, Section B, Line 15 Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer benchmarking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Section C, Line 19 The Foundation's governing documents, conflicts of interest policy, and financial statements are provided upon request and are publicly available on the Foundation's website. Form 990, Part XI, Line 9 Includes increase (decrease) in fair value of funds held in trust by others, net investment losses in excess of gains (losses) designated for operations and pension related changes other than net periodic pension costs.